Estudio de decorina durante la gestación en el humano y en la rata

Vista sencilla de ítem
dc.contributor.advisorCaminos Pinzón., Jorge Eduardo
dc.contributor.advisorGarcés Gutiérrez, María Fernanda
dc.contributor.authorCano Bermúdez, María Alejandra
dc.contributor.researchgroupEndocrinología y Nutrición Básicaspa
dc.date.accessioned2023-08-30T13:37:07Z
dc.date.available2023-08-30T13:37:07Z
dc.date.issued2022-07-07
dc.descriptionilustraciones, diagramasspa
dc.description.abstractDecorina (DCN) es un proteoglicano con funciones sobre la regulación de factores de crecimiento. El objetivo fue determinar los niveles séricos de DCN en gestantes sanas (GN) y con preeclampsia (GP), y los niveles séricos y la expresión de DCN en rata. En humano se incluyeron; GN (n= 50) y GP (n= 20), mujeres tres meses posparto (PP) (n=22) y mujeres no gestantes (NG) (n= 20). En Rata (Rattus norvegicus) se realizó un estudio experimental, se conformaron grupos de 12, 16 y 21 días de gestación y un grupo virgen control. Se usó ELISA para cuantificar DCN en humano y rata, qPCR e inmunohistoquímica. Los resultados mostraron que los niveles séricos de DCN disminuyeron significativamente en GN y GP en comparación con NG (p < 0.001) y PP (p < 0.001). Durante el tercer trimestre, DCN fue significativamente más alto en GP que GN (p < 0.01). En rata DCN no presentó cambios significativos entre la gestación y el grupo virgen control (p > 0.05). La expresión de mRNA de Dcn en placenta fue superior en 12d que en 16d y 21d (p >0.001), y en placenta de 12d DCN se distribuyó en el estroma de las vellosidades coriónicas. En conclusión, los niveles séricos de DCN disminuyeron durante la gestación en mujer y en rata. DCN no represento utilidad diagnóstica en GP. DCN inhiben diferentes factores de crecimiento como factor de crecimiento transformante-beta (TGF-β), y su disminución durante la gestación puede estar relacionada con favorecer la angiogénesis. (Texto tomado de la fuente)spa
dc.description.abstractDecorin (DCN) is a proteoglycan with functions on the regulation of growth factors. The objective was to determine the serum levels of DCN in healthy pregnant women (GN) and those with preeclampsia (GP), and the serum levels and expression of DCN in rats. In humans they included; GN (n= 50) and GP (n= 20), women three months postpartum (PP) (n=22) and non-pregnant women (NG) (n= 20). In Rat (Rattus norvegicus) an experimental study was carried out, groups of 12, 16 and 21 days of gestation and a virgin control group were formed. ELISA was used to quantify human and rat DCN, qPCR and immunohistochemistry. The results showed that serum levels of DCN were significantly decreased in GN and GP compared to NG (p < 0.001) and PP (p < 0.001). During the third trimester, DCN was significantly higher in GP than GN (p < 0.01). In the DCN rat, there were no significant changes between gestation and the virgin control group (p > 0.05). DCN mRNA expression in placenta was higher at 12d than at 16d and 21d (p >0.001), and in 12d placenta DCN was distributed in the chorionic villus stroma. In conclusion, serum levels of DCN decreased during pregnancy in women and in rats. DCN does not represent diagnostic utility in GP. DCN inhibit different growth factors such as transforming growth factor-beta (TGF-β), and its decrease during pregnancy may be related to favoring angiogenesis.eng
dc.description.degreelevelMaestríaspa
dc.description.methodsEl presente trabajo está clasificado como un estudio retrospectivo, anidado, de casos y controles – observacional y fue llevado a cabo en una cohorte longitudinal de mujeres gestantes seguidas durante la gestación y el posparto, y en mujeres sanas no gestantes.spa
dc.description.researchareafisiología de la gestaciónspa
dc.description.sponsorship“Valor de biomarcadores séricos en la predicción del desenlace materno-perinatal de la gestante y su evolución a 6 meses”, financiado por Colciencias código 110154531660 y aprobado por el Comité de Ética de la Facultad de Medicina de la Universidad Nacional de Colombia, en el acta número 17 del 13 de octubre 2011.spa
dc.format.extentxi, 116 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/84614
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Bioquímicaspa
dc.relation.referencesH. Stepan, M. Hund, and T. Andraczek, “Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia,” Hypertension, pp. 918–926, 2020.spa
dc.relation.referencesA. F. Sunjaya and A. P. Sunjaya, “Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia,” J. Fam. Reprod. Heal., vol. 13, no. 2, p. 56, Jun. 2019.spa
dc.relation.referencesS. Capriglione et al., “Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature,” https://doi.org/10.1080/14767058.2018.1495191, vol. 33, no. 4, pp. 677–686, Feb. 2018.spa
dc.relation.referencesS. M. Lee et al., “Metabolomic biomarkers in midtrimester maternal plasma can accurately predict the development of preeclampsia,” Sci. Reports 2020 101, vol. 10, no. 1, pp. 1–11, Sep. 2020.spa
dc.relation.referencesInstituto Nacional de Salud de Colombia, “Boletín Epidemiológico Semana epidemiológica 53 de 2020,” Bogota , 2021.spa
dc.relation.referencesK. S. Khan, D. Wojdyla, L. Say, A. M. Gülmezoglu, and P. F. Van Look, “WHO analysis of causes of maternal death: a systematic review,” Lancet, vol. 367, no. 9516, pp. 1066–1074, Apr. 2006.spa
dc.relation.referencesINSTITUTO NACIONAL DE SALUD, “Boletín Epidemiológico Semanal. Semana 52 de 2021 Colombia.,” 2021.spa
dc.relation.referencesN. D. Paauw and A. T. Lely, “Cardiovascular Sequels During and After Preeclampsia,” in Advances in experimental medicine and biology, vol. 1065, 2018, pp. 455–470.spa
dc.relation.referencesN. D. Paauw, K. Luijken, A. Franx, M. C. Verhaar, and A. T. Lely, “Long-term renal and cardiovascular risk after preeclampsia: towards screening and prevention,” Clin. Sci., vol. 130, no. 4, pp. 239–246, Jan. 2016.spa
dc.relation.referencesM. F. Garcés et al., “Maternal Serum Meteorin Levels and the Risk of Preeclampsia.,” PLoS One, vol. 10, no. 6, p. e0131013, Jun. 2015.spa
dc.relation.referencesG. MF et al., “Irisin levels during pregnancy and changes associated with the development of preeclampsia,” J. Clin. Endocrinol. Metab., vol. 99, no. 6, pp. 2113–2119, 2014.spa
dc.relation.references“Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222,” Obstetrics and gynecology, vol. 135, no. 6. NLM (Medline), pp. 1492–1495, 01-Jun-2020.spa
dc.relation.referencesM. J. Soares, D. Chakraborty, M. A. Karim Rumi, T. Konno, and S. J. Renaud, “Rat placentation: An experimental model for investigating the hemochorial maternal-fetal interface,” Placenta, vol. 33, no. 4, pp. 233–243, Apr. 2012.spa
dc.relation.referencesM. J. Soares, K. M. Varberg, and K. Iqbal, “Hemochorial placentation: development, function, and adaptations,” Biol. Reprod., vol. 99, no. 1, p. 196, Jul. 2018.spa
dc.relation.referencesL. Schaefer and R. V. Iozzo, “Biological functions of the small leucine-rich proteoglycans: From genetics to signal transduction,” Journal of Biological Chemistry, vol. 283, no. 31. American Society for Biochemistry and Molecular Biology, pp. 21305–21309, 01-Aug-2008.spa
dc.relation.referencesT. Krusius and E. Ruoslahti, “Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA.,” Proc. Natl. Acad. Sci., vol. 83, no. 20, pp. 7683–7687, Oct. 1986.spa
dc.relation.referencesL. W. Fisher, J. D. Termine, and M. F. Young, “Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species.,” J. Biol. Chem., vol. 264, no. 8, pp. 4571–6, Mar. 1989.spa
dc.relation.referencesR. V. Iozzo, D. K. Moscatello, D. J. McQuillan, and I. Eichstetter, “Decorin Is a Biological Ligand for the Epidermal Growth Factor Receptor,” J. Biol. Chem., vol. 274, no. 8, pp. 4489–4492, Feb. 1999.spa
dc.relation.referencesC. C. Reed and R. V. Iozzo, “The role of decorin in collagen fibrillogenesis and skin homeostasis,” Glycoconj. J., vol. 19, no. 4/5, pp. 249–255, May 2002.spa
dc.relation.referencesD. K. Moscatello, M. Santra, D. M. Mann, D. J. McQuillan, A. J. Wong, and R. V Iozzo, “Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor.,” J. Clin. Invest., vol. 101, no. 2, pp. 406–412, Jan. 1998.spa
dc.relation.referencesM. Ständer, U. Naumann, W. Wick, and M. Weller, “Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth.,” Cell Tissue Res., vol. 296, no. 2, pp. 221–7, May 1999.spa
dc.relation.referencesK. Baghy et al., “Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis,” FEBS J., vol. 280, no. 10, pp. 2150–2164, May 2013.spa
dc.relation.referencesB. Bozoky, A. Savchenko, H. Guven, F. Ponten, G. Klein, and L. Szekely, “Decreased decorin expression in the tumor microenvironment,” Cancer Med., vol. 3, no. 3, pp. 485–491, Jun. 2014.spa
dc.relation.referencesR. V. Iozzo and R. D. Sanderson, “Proteoglycans in cancer biology, tumour microenvironment and angiogenesis,” Journal of Cellular and Molecular Medicine, vol. 15, no. 5. Wiley-Blackwell, pp. 1013–1031, May-2011.spa
dc.relation.referencesGene - NCBI, “DCN decorin [Homo sapiens (human)],” 12-Sep-2021. [Online]. Available: https://www.ncbi.nlm.nih.gov/gene/1634. [Accessed: 28-Oct-2021].spa
dc.relation.referencesE. Rødahl, R. Van Ginderdeuren, P. M. Knappskog, C. Bredrup, and H. Boman, “A Second Decorin Frame Shift Mutation in a Family With Congenital Stromal Corneal Dystrophy,” Am. J. Ophthalmol., vol. 142, no. 3, pp. 520–521, Sep. 2006.spa
dc.relation.referencesC. Bredrup, P. M. Knappskog, J. Majewski, E. Rødahl, and H. Boman, “Congenital Stromal Dystrophy of the Cornea Caused by a Mutation in the Decorin Gene,” Investig. Opthalmology Vis. Sci., vol. 46, no. 2, p. 420, Feb. 2005.spa
dc.relation.referencesL. Pulkkinen, T. Alitalo, T. Krusius, and L. Peltonen, “Expression of decorin in human tissues and cell lines and defined chromosomal assignment of the gene locus (DCN),” Cytogenet. Genome Res., vol. 60, no. 2, pp. 107–111, 1992.spa
dc.relation.referencesJ. J. Lysiak, J. Hunt, G. A. Pringle, and P. K. Lala, “Localization of transforming growth factor beta and its natural inhibitor decorin in the human placenta and decidua throughout gestation.,” Placenta, vol. 16, no. 3, pp. 221–31, Apr. 1995.spa
dc.relation.referencesD. Iacob et al., “Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors,” Endocrinology, vol. 149, no. 12, pp. 6187–6197, Dec. 2008.spa
dc.relation.referencesG. A. Khan, G. V. Girish, N. Lala, G. M. di Guglielmo, and P. K. Lala, “Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast,” Mol. Endocrinol., vol. 25, no. 8, pp. 1431–1443, Aug. 2011.spa
dc.relation.referencesM. A. Gubbiotti, S. D. Vallet, S. Ricard-Blum, and R. V. Iozzo, “Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions,” Matrix Biol., vol. 55, pp. 7–21, Sep. 2016.spa
dc.relation.referencesK. Moreth, R. V. Iozzo, and L. Schaefer, “Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation,” Cell Cycle, vol. 11, no. 11. Taylor and Francis Inc., pp. 2084–2091, 01-Jun-2012.spa
dc.relation.referencesT. Neill et al., “Decorin antagonizes the angiogenic network: Concurrent inhibition of met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and tiMP3,” J. Biol. Chem., vol. 287, no. 8, pp. 5492–5506, Feb. 2012.spa
dc.relation.referencesA. De Luca, M. Santra, A. Baldi, A. Giordano, and R. V. Iozzo, “Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases,” J. Biol. Chem., vol. 271, no. 31, pp. 18961–18965, 1996.spa
dc.relation.referencesA. Carlin and Z. Alfirevic, “Physiological changes of pregnancy and monitoring,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 22, no. 5, pp. 801–823, Oct. 2008.spa
dc.relation.referencesE. R. Lumbers and K. G. Pringle, “Roles of the circulating renin-angiotensin-aldosterone system in human pregnancy,” Am. J. Physiol. Integr. Comp. Physiol., vol. 306, no. 2, pp. R91–R101, Jan. 2014.spa
dc.relation.referencesP. Soma-Pillay, C. Nelson-Piercy, H. Tolppanen, and A. Mebazaa, “Physiological changes in pregnancy,” Cardiovasc. J. Afr., vol. 27, no. 2, pp. 89–94, May 2016.spa
dc.relation.referencesE. K. Tan and E. L. Tan, “Alterations in physiology and anatomy during pregnancy,” Best Pract. Res. Clin. Obstet. Gynaecol., vol. 27, no. 6, pp. 791–802, Dec. 2013.spa
dc.relation.referencesM. Sanghavi and J. D. Rutherford, “Cardiovascular Physiology of Pregnancy,” Circulation, vol. 130, no. 12, pp. 1003–1008, Sep. 2014.spa
dc.relation.referencesK. Leidecker and K. Dorman, “Pulmonary Disorders Complicating Pregnancy: An Overview.,” J. Perinat. Neonatal Nurs., vol. 30, no. 1, pp. 45–53, 2016.spa
dc.relation.referencesY. Liu, X. Ma, J. Zheng, X. Liu, and T. Yan, “A Systematic Review and Meta-Analysis of Kidney and Pregnancy Outcomes in IgA Nephropathy,” Am. J. Nephrol., vol. 44, no. 3, pp. 187–193, 2016.spa
dc.relation.referencesC. H. Leo et al., “Vascular actions of relaxin: nitric oxide and beyond.,” Br. J. Pharmacol., vol. 174, no. 10, pp. 1002–1014, 2017.spa
dc.relation.referencesG. Valdes, P. Kaufmann, J. Corthorn, R. Erices, K. B. Brosnihan, and J. Joyner-Grantham, “Vasodilator factors in the systemic and local adaptations to pregnancy.,” Reprod. Biol. Endocrinol., vol. 7, p. 79, Jul. 2009.spa
dc.relation.referencesD. R. Hadden and C. McLaughlin, “Normal and abnormal maternal metabolism during pregnancy,” Semin. Fetal Neonatal Med., vol. 14, no. 2, pp. 66–71, Apr. 2009.spa
dc.relation.referencesF. Visiedo, F. Bugatto, R. Quintero-Prado, I. Cózar-Castellano, J. L. Bartha, and G. Perdomo, “Glucose and Fatty Acid Metabolism in Placental Explants From Pregnancies Complicated With Gestational Diabetes Mellitus,” Reprod. Sci., vol. 22, no. 7, pp. 798–801, Jul. 2015.spa
dc.relation.referencesS. W. Ng, G. A. Norwitz, M. Pavlicev, T. Tilburgs, C. Simón, and E. R. Norwitz, “Endometrial Decidualization: The Primary Driver of Pregnancy Health,” Int. J. Mol. Sci., vol. 21, no. 11, pp. 1–20, Jun. 2020.spa
dc.relation.referencesL. M. R. Ferreira, T. B. Meissner, T. Tilburgs, and J. L. Strominger, “HLA-G: At the Interface of Maternal-Fetal Tolerance,” Trends Immunol., vol. 38, no. 4, pp. 272–286, Apr. 2017.spa
dc.relation.referencesA. Dixit and A. A. Karande, “Glycodelin regulates the numbers and function of peripheral natural killer cells,” J. Reprod. Immunol., vol. 137, Feb. 2020.spa
dc.relation.referencesS. Rajagopalan and E. O. Long, “A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells,” J. Exp. Med., vol. 189, no. 7, pp. 1093–1099, Apr. 1999.spa
dc.relation.referencesS. Rajagopalan et al., “Activation of NK cells by an endocytosed receptor for soluble HLA-G,” PLoS Biol., vol. 4, no. 1, pp. 0070–0086, 2006.spa
dc.relation.referencesR. Hackmon, A. Koifman, H. Hyobo, H. Glickman, E. Sheiner, and D. E. Geraghty, “Reduced third-trimester levels of soluble human leukocyte antigen G protein in severe preeclampsia,” Am. J. Obstet. Gynecol., vol. 197, no. 3, pp. 255.e1-255.e5, 2007.spa
dc.relation.referencesM. O’Brien et al., “Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease,” Cell. Mol. Life Sci., vol. 58, no. 12–13, pp. 1943–1949, 2001.spa
dc.relation.referencesM. B. Brown, M. von Chamier, A. B. Allam, and L. Reyes, “M1/M2 Macrophage Polarity in Normal and Complicated Pregnancy,” Front. Immunol., vol. 5, no. NOV, 2014.spa
dc.relation.referencesY. Yao, X. H. Xu, and L. Jin, “Macrophage Polarization in Physiological and Pathological Pregnancy,” Front. Immunol., vol. 10, no. MAR, 2019.spa
dc.relation.referencesA. Torchinsky et al., “TNF-alpha protects embryos exposed to developmental toxicants,” Am. J. Reprod. Immunol., vol. 49, no. 3, pp. 159–168, Mar. 2003.spa
dc.relation.referencesW. Wang, N. Sung, A. Gilman-Sachs, and J. Kwak-Kim, “T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells,” Front. Immunol., vol. 11, Aug. 2020.spa
dc.relation.referencesS. A. Robertson, A. S. Care, and L. M. Moldenhauer, “Regulatory T cells in embryo implantation and the immune response to pregnancy,” J. Clin. Invest., vol. 128, no. 10, p. 4224, Oct. 2018.spa
dc.relation.referencesD. D. Carson et al., “Embryo Implantation,” Dev. Biol., vol. 223, no. 2, pp. 217–237, Jul. 2000.spa
dc.relation.referencesC. Bergeron, “Histología y fisiología del endometrio normal,” EMC - Ginecol., vol. 42, no. 4, pp. 1–8, Jan. 2006.spa
dc.relation.referencesC. L. Dunn, R. W. Kelly, and H. O. D. Critchley, “Decidualization of the human endometrial stromal cell: an enigmatic transformation,” Reprod. Biomed. Online, vol. 7, no. 2, pp. 151–161, 2003.spa
dc.relation.referencesU. Kämmerer, M. von Wolff, and U. R. Markert, “Immunology of human endometrium,” Immunobiology, vol. 209, no. 7, pp. 569–574, Nov. 2004.spa
dc.relation.referencesS. F. De Medeiros, B. B. Barbosa, M. A. S. De Medeiros, and M. M. W. Yamamoto, “Morphology and Biochemistry of Ovulation,” Rev. Bras. Ginecol. Obstet., vol. 43, no. 6, pp. 480–486, Jun. 2021.spa
dc.relation.referencesH. Wang et al., “Physiological and molecular determinants of embryo implantation,” Mol. Aspects Med., vol. 34, no. 5, p. 939, Oct. 2013.spa
dc.relation.referencesT. W. Sadler and J. Langman, Langman embriología médica: con orientación clínica. Ed. Médica Panamericana, 2007.spa
dc.relation.referencesJ.-L. Maître, “Mechanics of blastocyst morphogenesis,” Biol. Cell, vol. 109, no. 9, pp. 323–338, Sep. 2017.spa
dc.relation.referencesB. C. Paria, J. Reese, S. K. Das, and S. K. Dey, “Deciphering the Cross-Talk of Implantation: Advances and Challenges,” Science (80-. )., vol. 296, no. 5576, pp. 2185–2188, Jun. 2002.spa
dc.relation.referencesC. H. Graham and P. K. Lala, “Mechanisms of placental invasion of the uterus and their control,” Biochem. Cell Biol., vol. 70, no. 10–11, pp. 867–874, Oct. 1992.spa
dc.relation.referencesG. Osol and M. Mandala, “Maternal Uterine Vascular Remodeling During Pregnancy,” Physiology (Bethesda)., vol. 24, no. 1, p. 58, Feb. 2009.spa
dc.relation.referencesG. J. Burton and A. L. Fowden, “The placenta: a multifaceted, transient organ,” Philos. Trans. R. Soc. B Biol. Sci., vol. 370, no. 1663, p. 20140066, Mar. 2015.spa
dc.relation.referencesE. A. Steegers, P. von Dadelszen, J. J. Duvekot, and R. Pijnenborg, “Pre-eclampsia,” Lancet, vol. 376, no. 9741, pp. 631–644, Aug. 2010.spa
dc.relation.referencesB. M. Sibai, “The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): Much ado about nothing?,” Am. J. Obstet. Gynecol., vol. 162, no. 2, pp. 311–316, Feb. 1990.spa
dc.relation.referencesA. Conde-Agudelo and J. M. Belizan, “Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women,” BJOG An Int. J. Obstet. Gynaecol., vol. 107, no. 1, pp. 75–83, Jan. 2000.spa
dc.relation.referencesG. A. Dekker and B. M. Sibai, “Etiology and pathogenesis of preeclampsia: Current concepts,” Am. J. Obstet. Gynecol., vol. 179, no. 5, pp. 1359–1375, Nov. 1998.spa
dc.relation.referencesJ. James, “Overview of Human Implantation,” in Pathobiology of Human Disease, Elsevier, 2014, pp. 2293–2307.spa
dc.relation.referencesB. Huppertz, “Human Placentation,” in Encyclopedia of Reproduction, Elsevier, 2018, pp. 431–439.spa
dc.relation.referencesC. W. G. Redman, “Pre-eclampsia and the placenta,” Placenta, vol. 12, no. 4, pp. 301–308, Jul. 1991.spa
dc.relation.referencesC. W. Ives, R. Sinkey, I. Rajapreyar, A. T. N. Tita, and S. Oparil, “Preeclampsia—Pathophysiology and Clinical Presentations,” J. Am. Coll. Cardiol., vol. 76, no. 14, pp. 1690–1702, Oct. 2020.spa
dc.relation.referencesJ. R. Lindsey and H. J. Baker, “Historical Foundations,” in The Laboratory Rat, Elsevier, 2006, pp. 1–52.spa
dc.relation.referencesH. J. Hedrich, “Taxonomy and Stocks and Strains,” in The Laboratory Rat, Elsevier, 2006, pp. 71–92.spa
dc.relation.referencesG. Krinke, The Laboratory Rat - 1st Edition, 1st ed., vol. 1. New York: Academic Press, 2000.spa
dc.relation.referencesJ. J. Lohmiller and S. P. Swing, “Reproduction and Breeding,” in The Laboratory Rat, Elsevier, 2006, pp. 147–164.spa
dc.relation.referencesJ. J. Lohmiller, S. P. Swing, and M. M. Hanson, “Reproduction and Breeding,” in The Laboratory Rat, Elsevier, 2020, pp. 157–179.spa
dc.relation.referencesB. O. Karim et al., “Estrous cycle and ovarian changes in a rat mammary carcinogenesis model after irradiation, tamoxifen chemoprevention, and aging.,” Comp. Med., vol. 53, no. 5, pp. 532–8, Oct. 2003.spa
dc.relation.referencesG. Coticchio, C. Lagalla, R. Sturmey, F. Pennetta, and A. Borini, “The enigmatic morula: mechanisms of development, cell fate determination, self-correction and implications for ART,” Hum. Reprod. Update, vol. 25, no. 4, pp. 422–438, Jul. 2019.spa
dc.relation.referencesC. Erb, “Embryology and Teratology,” in The Laboratory Rat, Elsevier, 2006, pp. 817–846.spa
dc.relation.referencesM. J. Soares and J. S. Hunt, Placenta and Trophoblast: Methods and Protocols, Volume 1. Springer Science & Business Media, 2006.spa
dc.relation.referencesR. W. Dudek, Embryology. Lippincott Williams & Wilkins, 2010.spa
dc.relation.referencesM. M. Sebastian and T. M. Borjeson, “Embryology and Teratology,” in The Laboratory Rat, Elsevier, 2020, pp. 863–890.spa
dc.relation.referencesS. S. C. Yen, R. B. Jaffe, and R. L. Barbieri, Endocrinología de la reproducción: fisiología, fisiopatología y manejo clínico. Ed. Médica Panamericana, 2001.spa
dc.relation.referencesS. F. Gilbert, Biología del desarrollo. Ed. Médica Panamericana, 2005.spa
dc.relation.referencesL. Wolpert, Principios del desarrollo. Ed. Médica Panamericana, 2009.spa
dc.relation.referencesJ. W. Rohen and E. Lütjen-Drecoll, Embriología funcional: una perspectiva desde la biología del desarrollo. Ed. Médica Panamericana, 2007.spa
dc.relation.referencesL. Puelles, B. Fernández, and M. Martínez-De-La-Torre, “Neuromeric Landmarks in the Rat Midbrain, Diencephalon and Hypothalamus, Compared with Acetylcholinesterase Histochemistry,” in The Rat Nervous System, Elsevier, 2015, pp. 25–43.spa
dc.relation.referencesR. M. Eakin, Vertebrate Embryology: A Laboratory Manual. University of California Press, 1978.spa
dc.relation.referencesT. Gogiel, E. Bańkowski, and S. Jaworski, “Pre-Eclampsia-Associated Differential Expression of Proteoglycans in the Umbilical Cord Arteries,” Pathobiology, vol. 69, no. 4, pp. 212–218, 2001spa
dc.relation.referencesT. Gogiel, Z. S. J. Galewska, and S. Jaworski, “Pre-eclampsia-associated alterations in Wharton’s jelly proteoglycans ,” Acta Biochim. Pol., vol. 52, no. 2, pp. 501–505, 2005.spa
dc.relation.referencesT. Gogiel, Z. Galewska, L. Romanowicz, S. Jaworski, and E. Bańkowski, “Pre-eclampsia-associated alterations in decorin, biglycan and versican of the umbilical cord vein wall,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 134, no. 1, pp. 51–56, 2007.spa
dc.relation.referencesN. Lala, G. V. Girish, A. Cloutier-Bosworth, and P. K. Lala, “Mechanisms in decorin regulation of vascular endothelial growth factor-induced human trophoblast migration and acquisition of endothelial phenotype,” Biol. Reprod., vol. 87, no. 3, pp. 59–60, Sep. 2012.spa
dc.relation.referencesA. Chui, P. Murthi, S. P. Brennecke, V. Ignjatovic, P. T. Monagle, and J. M. Said, “The expression of placental proteoglycans in pre-eclampsia,” Gynecol. Obstet. Invest., vol. 73, no. 4, pp. 277–284, Jun. 2012.spa
dc.relation.referencesY. Zou et al., “Decorin-Mediated Inhibition of Human Trophoblast Cells Proliferation, Migration, and Invasion and Promotion of Apoptosis In Vitro,” Biomed Res. Int., vol. 2015, pp. 1–10, 2015.spa
dc.relation.referencesK. Daglar, A. Kirbas, H. Timur, Z. Ozturk Inal, and N. Danisman, “Placental levels of total oxidative and anti-oxidative status, ADAMTS-12 and decorin in early- and late-onset severe preeclampsia,” J. Matern. Neonatal Med., vol. 29, no. 24, pp. 4059–4064, Dec. 2016.spa
dc.relation.referencesM. F. Siddiqui et al., “Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker,” Am. J. Obstet. Gynecol., vol. 215, no. 3, pp. 361.e1-361.e15, Sep. 2016.spa
dc.relation.referencesI. Uzun Cilingir et al., “Placental and serum levels of human Klotho in severe preeclampsia: A potential sensitive biomarker,” Placenta, vol. 85, pp. 49–55, Sep. 2019.spa
dc.relation.referencesG. Adanas Aydin, H. Ayvaci, and G. Özgen, “The first-trimester serum decorin levels as a potential predictor of preeclampsia,” J. Perinat. Med., vol. 48, no. 8, pp. 779–785, Oct. 2020.spa
dc.relation.referencesG. Özgen and G. A. Aydın, “Decorin levels in early- and late-onset preeclampsia,” Ginekol. Pol., vol. 91, no. 5, pp. 262–268, 2020.spa
dc.relation.referencesL. Alkema et al., “Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group.,” Lancet (London, England), vol. 387, no. 10017, pp. 462–74, Jan. 2016.spa
dc.relation.referencesA. Conde-Agudelo, J. M. Belizán, and C. Lammers, “Maternal-perinatal morbidity and mortality associated with adolescent pregnancy in Latin America: Cross-sectional study,” Am. J. Obstet. Gynecol., vol. 192, no. 2, pp. 342–349, Feb. 2005.spa
dc.relation.referencesL. Say et al., “Global causes of maternal death: a WHO systematic analysis.,” Lancet. Glob. Heal., vol. 2, no. 6, pp. e323-33, Jun. 2014.spa
dc.relation.referencesW. S. Aronow, “Hypertensive disorders in pregnancy.,” Ann. Transl. Med., vol. 5, no. 12, p. 266, Jun. 2017.spa
dc.relation.referencesE. Phipps, D. Prasanna, W. Brima, and B. Jim, “Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines.,” Clin. J. Am. Soc. Nephrol., vol. 11, no. 6, pp. 1102–13, 2016.spa
dc.relation.referencesJ. Pereira Calvo, Y. Pereira Rodríguez, and L. Quirós Figueroa, “Actualización en preeclampsia,” Rev. Medica Sinerg., vol. 5, no. 1, p. e340, Jan. 2020.spa
dc.relation.referencesS. Lim, W. Li, J. Kemper, A. Nguyen, B. W. Mol, and M. Reddy, “Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis,” Obstet. Gynecol., vol. 137, no. 1, pp. 72–81, Jan. 2021.spa
dc.relation.referencesP. W. F. Wilson et al., “Estimation of VLDL cholesterol in hyperlipidemia,” Clin. Chim. Acta, vol. 151, no. 3, pp. 285–291, Oct. 1985.spa
dc.relation.referencesD. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, Jul. 1985.spa
dc.relation.references“Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222,” Obstetrics and gynecology, vol. 135, no. 6. NLM (Medline), pp. 1492–1495, Jun-2020.spa
dc.relation.referencesX. EM, P. JM, F. N, C. D, and L. O, “Preeclampsia: is induction of labor more successful?,” Obstet. Gynecol., vol. 89, no. 4, pp. 600–603, Apr. 1997.spa
dc.relation.referencesB. K, P. B, N.-P. C, S. PT, P. L, and C. LC, “Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis,” BMJ, vol. 348, Apr. 2014.spa
dc.relation.referencesC. KH and P. WJ, “Severe preeclampsia and delivery outcomes: is immediate cesarean delivery beneficial?,” Am. J. Obstet. Gynecol., vol. 186, no. 5, pp. 921–923, 2002.spa
dc.relation.referencesN. AH, A. AM, C. N, G.-M. O, and B. S, “Severe preeclampsia remote from term: labor induction or elective cesarean delivery?,” Am. J. Obstet. Gynecol., vol. 179, no. 5, pp. 1210–1213, 1998.spa
dc.relation.referencesK. LH, C. YW, D. S, J. AC, and C. AB, “Is preeclampsia associated with an increased risk of cesarean delivery if labor is induced?,” J. Matern. Fetal. Neonatal Med., vol. 23, no. 5, pp. 383–388, May 2010.spa
dc.relation.referencesP. K. Lala and P. Nandi, “Mechanisms of trophoblast migration, endometrial angiogenesis in preeclampsia: The role of decorin.,” Cell Adh. Migr., vol. 10, no. 1–2, pp. 111–25, 2016.spa
dc.relation.referencesH. Järveläinen, A. Sainio, and T. N. Wight, “Pivotal role for decorin in angiogenesis,” Matrix Biology, vol. 43. Elsevier, pp. 15–26, 01-Apr-2015.spa
dc.relation.referencesD. D. Sofeu Feugaing, M. Götte, and M. Viola, “More than matrix: The multifaceted role of decorin in cancer,” European Journal of Cell Biology, vol. 92, no. 1. Eur J Cell Biol, pp. 1–11, Jan-2013.spa
dc.relation.referencesA. Morrione, T. Neill, and R. V. Iozzo, “Dichotomy of decorin activity on the insulin-like growth factor-I system,” FEBS Journal, vol. 280, no. 10. FEBS J, pp. 2138–2149, May-2013.spa
dc.relation.referencesP. K. Lala and G. S. Hamilton, “Growth factors, proteases and protease inhibitors in the maternal-fetal dialogue,” Placenta, vol. 17, no. 8, pp. 545–555, 1996.spa
dc.relation.referencesM. Knöfler, “Critical growth factors and signalling pathways controlling human trophoblast invasion,” Int. J. Dev. Biol., vol. 54, no. 2–3, pp. 269–280, 2010.spa
dc.relation.referencesY. Yamaguchi, D. M. Mann, and E. Ruoslahti, “Negative regulation of transforming growth factor-β by the proteoglycan decorin,” Nature, vol. 346, no. 6281, pp. 281–284, 1990.spa
dc.relation.referencesK. Imai, A. Hiramatsu, D. Fukushima, M. D. Pierschbacher, and Y. Okada, “Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release,” Biochem. J., vol. 322, no. 3, pp. 809–814, Mar. 1997.spa
dc.relation.referencesN. Ferrara, “The role of VEGF in the regulation of physiological and pathological angiogenesis.,” EXS, no. 94. EXS, pp. 209–231, 2005.spa
dc.relation.referencesM. Van Bockstal et al., “Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion,” Oncoscience, vol. 1, no. 10, pp. 634–648, 2014.spa
dc.relation.referencesC. W. Redman and I. L. Sargent, “Latest advances in understanding preeclampsia,” Science, vol. 308, no. 5728, pp. 1592–1594, Jun. 2005.spa
dc.relation.referencesM. F. Siddiqui et al., “Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker,” Am. J. Obstet. Gynecol., vol. 215, no. 3, pp. 361.e1-361.e15, Sep. 2016.spa
dc.relation.referencesE. Domínguez Alonso and González Suárez, “Análisis de las curvas receiver-operating characteristic: un método útil para evaluar procederes diagnósticos,” Rev. Cuba. Endocrinol., vol. 13, no. 2, May 2002.spa
dc.relation.referencesJ. Cerda and L. Cifuentes, “Uso de curvas ROC en investigación clínica: Aspectos teórico-prácticos,” Rev. Chil. infectología, vol. 29, no. 2, pp. 138–141, Apr. 2012.spa
dc.relation.referencesM. Jamioł, J. Wawrzykowski, and M. Kankofer, “The influence of progesterone and prostaglandin F2α on decorin and the adhesion of caruncular epithelial cells of bovine placenta at early-mid pregnancy—Part II,” Reprod. Domest. Anim., vol. 56, no. 7, pp. 1040–1049, Jul. 2021.spa
dc.relation.referencesA. Kedem, K. Ulanenko-Shenkar, Y. Yung, G. M. Yerushalmi, E. Maman, and A. Hourvitz, “Elucidating Decorin’s role in the preovulatory follicle,” J. Ovarian Res., vol. 13, no. 1, Feb. 2020.spa
dc.relation.referencesY. J. Ono et al., “Decorin induced by progesterone plays a crucial role in suppressing endometriosis,” J. Endocrinol., vol. 223, no. 2, p. 203, 2014.spa
dc.relation.referencesH. CD, N. P, J. MJ, R. SJ, and L. PK, “Decorin production by the human decidua: role in decidual cell maturation,” Mol. Hum. Reprod., vol. 26, no. 10, pp. 784–796, Oct. 2020.spa
dc.relation.referencesC.-P. Chen, S.-C. Chang, and W.-C. Vivian Yang, “High Glucose Alters Proteoglycan Expression and the Glycosaminoglycan Composition in Placentas of Women with Gestational Diabetes Mellitus and in Cultured Trophoblasts,” Placenta, vol. 28, no. 2–3, pp. 97–106, Feb. 2007.spa
dc.relation.referencesF. R. C. Giachini et al., “Maternal diabetes affects specific extracellular matrix components during placentation,” J. Anat., vol. 212, no. 1, p. 31, Jan. 2008.spa
dc.relation.referencesK. Bolton et al., “Decorin is a secreted protein associated with obesity and type 2 diabetes,” Int. J. Obes., vol. 32, no. 7, pp. 1113–1121, Jul. 2008.spa
dc.relation.referencesJ. Svärd et al., “Absence of the proteoglycan decorin reduces glucose tolerance in overfed male mice,” Sci. Rep., vol. 9, no. 1, p. 4614, Dec. 2019.spa
dc.relation.referencesJ. Zhang, W. Wright, D. A. Bernlohr, S. W. Cushman, and X. Chen, “Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance,” Am. J. Physiol. Metab., vol. 292, no. 5, pp. E1433–E1440, May 2007.spa
dc.relation.referencesT. W. L. Groeneveld et al., “Interactions of the Extracellular Matrix Proteoglycans Decorin and Biglycan with C1q and Collectins,” J. Immunol., vol. 175, no. 7, pp. 4715–4723, Oct. 2005.spa
dc.relation.referencesJ. Apaza Valencia, “Desarrollo placentario temprano: aspectos fisiopatológicos,” Rev. peru. ginecol. Obs. , vol. 60, no. 2, pp. 131–140, 2014.spa
dc.relation.referencesA. U. Borbely et al., “Decorin and biglycan immunolocalization in non-villous structures of healthy and pathological human placentas,” Histopathology, vol. 64, no. 5, pp. 616–625, 2014.spa
dc.relation.referencesG. GUTIERREZ MARTINEZ, Ariadne; GAMEZ MENENDEZ, Rafael; PARDO ACOSTA, Balia y MARRERO COFINO, “Longitud del ciclo estral en ratas Sprague Dawley tratadas in útero con extracto de Roystonea regia,” Rev Cuba. Farm [online], vol. vol.43, n.3., no. ISSN 0034-7515., 2009.spa
dc.relation.referencesJ. E. Caminos et al., “Expression of Ghrelin in the Cyclic and Pregnant Rat Ovary,” Endocrinology, vol. 144, no. 4, pp. 1594–1602, Apr. 2003.spa
dc.relation.referencesE. Schönherr, N. Lugering, R. Stoll, W. Domschke, and H. Kresse, “Differences in Decorin and Biglycan Expression in Patients with Gastric Ulcer Healing,” Scand. J. Gastroenterol., vol. 32, no. 8, pp. 785–790, Jan. 1997.spa
dc.relation.referencesX. Bi et al., “Oncogenic activin C interacts with decorin in colorectal cancer in vivo and in vitro,” Mol. Carcinog., vol. 55, no. 11, pp. 1786–1795, Nov. 2016.spa
dc.relation.referencesK. Augoff, J. Rabczynski, R. Tabola, L. Czapla, K. Ratajczak, and K. Grabowski, “Immunohistochemical study of decorin expression in polyps and carcinomas of the colon.,” Med. Sci. Monit., vol. 14, no. 10, pp. CR530-5, Oct. 2008.spa
dc.relation.referencesK. Bolton, Segal, and Walder, “The small leucine-rich proteoglycan, biglycan, is highly expressed in adipose tissue of Psammomys obesus and is associated with obesity and type 2 diabetes,” Biol. Targets Ther., p. 67, Apr. 2012.spa
dc.relation.referencesS. Furukawa, N. Tsuji, and A. Sugiyama, “Morphology and physiology of rat placenta for toxicological evaluation,” J. Toxicol. Pathol., vol. 32, no. 1, pp. 1–17, 2019.spa
dc.relation.referencesS. Furukawa, S. Hayashi, K. Usuda, M. Abe, S. Hagio, and I. Ogawa, “Toxicological Pathology in the Rat Placenta,” J. Toxicol. Pathol., vol. 24, no. 2, pp. 95–111, 2011.spa
dc.relation.referencesP. M. Coan, N. Conroy, G. J. Burton, and A. C. Ferguson-Smith, “Origin and characteristics of glycogen cells in the developing murine placenta,” Dev. Dyn., vol. 235, no. 12, pp. 3280–3294, Dec. 2006.spa
dc.relation.referencesT. Batbayal, Y. Ishii, Y. Nomura, M. Watanabe, T. Yasuko, and S. Nakamura, “Change in decorin during aging of rat placenta,” Connect. Tissue Res., vol. 47, no. 4, pp. 235–241, Jul. 2006.spa
dc.relation.referencesC. Chakraborty, L. M. Gleeson, T. McKinnon, and P. K. Lala, “Regulation of human trophoblast migration and invasiveness,” Can. J. Physiol. Pharmacol., vol. 80, no. 2, pp. 116–124, Feb. 2002.spa
dc.relation.referencesG. Xu, M.-J. Guimond, C. Chakraborty, and P. K. Lala, “Control of Proliferation, Migration, and Invasiveness of Human Extravillous Trophoblast by Decorin, a Decidual Product1,” Biol. Reprod., vol. 67, no. 2, pp. 681–689, Aug. 2002.spa
dc.relation.referencesT. Fernández Romero, G. Suárez Román, and S. Clapés Hernández, “Protocolo para la citología vaginal directa de ratas de laboratorio,” Rev. Habanera Ciencias Médicas, ISSN-e 1729-519X, Vol. 20, No. 3, 2021, vol. 20, no. 3, p. 10, 2021.spa
dc.relation.referencesT. Rina Aritonang et al., “The Role of FSH, LH, Estradiol and Progesterone Hormone on Estrus Cycle of Female Rats,” Int. J. Sci. Basic Appl. Res. Int. J. Sci. Basic Appl. Res., vol. 35, no. 1, pp. 92–100, 2017.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/spa
dc.subject.armarcPregnancyeng
dc.subject.ddc570 - Biología::571 - Fisiología y temas relacionadosspa
dc.subject.decsEmbarazospa
dc.subject.decsEnfermedades urogenitales femeninas y complicaciones del embarazospa
dc.subject.decsFemale urogenital diseases and pregnancy complicationseng
dc.subject.lembPregnancyspa
dc.subject.proposalDCNspa
dc.subject.proposalPlacentaspa
dc.subject.proposalPreeclampsiaspa
dc.subject.proposalDecorineng
dc.subject.proposalPregnancyeng
dc.titleEstudio de decorina durante la gestación en el humano y en la rataspa
dc.title.translatedStudy of decorina during pregnancy in the human and in the rateng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentMaestrosspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.fundernamecolcienciasspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1026289197.2023.pdf
Tamaño:
3.44 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Bioquímica
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Ciencias - Bioquímica